Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, Borre M, Agerbæk M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00058-0. doi: 10.1016/j.eururo.2016.01.007. [Epub ahead of print]

PMID:
26803478
2.

Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness.

Whitehead B, Wu L, Hvam ML, Aslan H, Dong M, Dyrskjøt L, Ostenfeld MS, Moghimi SM, Howard KA.

J Extracell Vesicles. 2015 Dec 28;4:29685. doi: 10.3402/jev.v4.29685. eCollection 2015.

3.

Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.

Mortensen MM, Høyer S, Lynnerup AS, Ørntoft TF, Sørensen KD, Borre M, Dyrskjøt L.

Sci Rep. 2015 Nov 2;5:16018. doi: 10.1038/srep16018.

4.

High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.

Mortensen MM, Høyer S, Orntoft TF, Sørensen KD, Dyrskjøt L, Borre M.

BMC Cancer. 2014 Nov 21;14:859. doi: 10.1186/1471-2407-14-859.

5.

Comparative analysis of discrete exosome fractions obtained by differential centrifugation.

Jeppesen DK, Hvam ML, Primdahl-Bengtson B, Boysen AT, Whitehead B, Dyrskjøt L, Orntoft TF, Howard KA, Ostenfeld MS.

J Extracell Vesicles. 2014 Nov 6;3:25011. doi: 10.3402/jev.v3.25011. eCollection 2014.

6.

Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties.

Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, Jensen JB, Pedersen JS, Beck M, Theodorescu D, Borre M, Howard KA, Dyrskjøt L, Ørntoft TF.

Cancer Res. 2014 Oct 15;74(20):5758-71. doi: 10.1158/0008-5472.CAN-13-3512. Epub 2014 Sep 26.

7.

High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.

Laurberg JR, Jensen JB, Schepeler T, Borre M, Ørntoft TF, Dyrskjøt L.

BMC Cancer. 2014 Aug 30;14:638. doi: 10.1186/1471-2407-14-638.

8.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

9.

Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

Vedder MM, Márquez M, de Bekker-Grob EW, Calle ML, Dyrskjøt L, Kogevinas M, Segersten U, Malmström PU, Algaba F, Beukers W, Ørntoft TF, Zwarthoff E, Real FX, Malats N, Steyerberg EW.

PLoS One. 2014 Jun 6;9(6):e96849. doi: 10.1371/journal.pone.0096849. eCollection 2014.

10.

Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.

Hedegaard J, Thorsen K, Lund MK, Hein AM, Hamilton-Dutoit SJ, Vang S, Nordentoft I, Birkenkamp-Demtröder K, Kruhøffer M, Hager H, Knudsen B, Andersen CL, Sørensen KD, Pedersen JS, Ørntoft TF, Dyrskjøt L.

PLoS One. 2014 May 30;9(5):e98187. doi: 10.1371/journal.pone.0098187. eCollection 2014.

11.

Mutational context and diverse clonal development in early and late bladder cancer.

Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Høyer S, Borre M, Reinert T, Fristrup N, Dyrskjøt L, Shah S, Pedersen JS, Ørntoft TF.

Cell Rep. 2014 Jun 12;7(5):1649-63. doi: 10.1016/j.celrep.2014.04.038. Epub 2014 May 15.

12.

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.

Teo MT, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE.

Ann Oncol. 2014 Apr;25(4):877-83. doi: 10.1093/annonc/mdu014. Epub 2014 Mar 12.

13.

Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.

Jeppesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjøt L, Ørntoft TF, Larsen MR, Ostenfeld MS.

Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16. Erratum in: Proteomics. 2014 Nov;14(21-22):2628-9.

PMID:
24376083
14.

The use of molecular analyses in voided urine for the assessment of patients with hematuria.

Beukers W, Kandimalla R, van Houwelingen D, Kovacic H, Chin JF, Lingsma HF, Dyrskjot L, Zwarthoff EC.

PLoS One. 2013 Oct 15;8(10):e77657. doi: 10.1371/journal.pone.0077657. eCollection 2013.

15.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

PMID:
24018021
16.

The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.

Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, Papafotiou G, Hodny Z, Sosa-Pineda B, Wu XR, Klinakis A, Ørntoft T, Lukas J, Bartek J, Gorgoulis VG.

Cell Death Differ. 2013 Nov;20(11):1485-97. doi: 10.1038/cdd.2013.76. Epub 2013 Jul 12.

17.

A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.

Kandimalla R, Masius R, Beukers W, Bangma CH, Orntoft TF, Dyrskjot L, van Leeuwen N, Lingsma H, van Tilborg AA, Zwarthoff EC.

Clin Cancer Res. 2013 Sep 1;19(17):4760-9. doi: 10.1158/1078-0432.CCR-12-3276. Epub 2013 Jul 10.

18.

The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancer.

Christiansen A, Dyrskjøt L.

Cancer Lett. 2013 Apr 30;331(1):18-23. doi: 10.1016/j.canlet.2012.12.013. Epub 2012 Dec 23. Review.

PMID:
23268335
19.

Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, Orntoft TF, Zwarthoff EC.

J Urol. 2013 May;189(5):1945-51. doi: 10.1016/j.juro.2012.11.115. Epub 2012 Nov 28.

PMID:
23201384
20.

Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.

Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, Borre M, Ørntoft TF, Dyrskjøt L.

Am J Pathol. 2013 Feb;182(2):339-49. doi: 10.1016/j.ajpath.2012.10.017. Epub 2012 Nov 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk